BioRestorative Therapies, Inc. Announces Entry Into \$1 Million Revolving Credit Facility with Bowery Group LLC
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a clinical-stage biotechnology company, has filed a Form 8-K to announce a significant financing development: the company has entered into a Revolving Loan Agreement with Bowery Group LLC, providing access to a revolving credit facility of up to \$1,000,000. This new financial arrangement is structured to support BioRestorative’s general corporate purposes—including the financing of a planned Qualified Public Equity Offering.
Key Terms of the Revolving Credit Facility
- Maximum Principal Amount: \$1,000,000
- Interest Rate: 12% per annum
- Default Rate: 16% per annum
- Final Maturity Date: First anniversary of the Closing Date
- Use of Proceeds: General corporate purposes, including financing expenses related to a Qualified Public Equity Offering
- Right of First Refusal: Bowery Group LLC is granted a right of first refusal for any subsequent debt financing during the term of the facility
Material Definitive Agreements Filed
BioRestorative filed the full texts of the Revolving Loan Agreement and the form of Revolving Promissory Note as Exhibits 10.1 and 10.2, respectively. Investors are encouraged to review these documents for further specifics.
Strategic Implications for Shareholders
The entry into this credit facility is a material event for shareholders, as it provides the company with near-term liquidity and flexibility to pursue its growth plans. Notably, the facility is tied to the company’s efforts to consummate a Qualified Public Equity Offering of at least \$5 million—a move that could significantly impact the company’s capital structure and growth trajectory. If successful, this offering could dilute existing shareholders but also strengthen the balance sheet and support ongoing clinical and commercial initiatives.
The credit agreement also includes provisions restricting certain corporate actions without lender consent, including amendments to organizational documents, repurchases of equity, dividend payments, and related-party transactions. These covenants are designed to protect lender interests and may affect future corporate strategies.
Potential Price Sensitive Information
- The company’s intent and obligation to pursue a Qualified Public Equity Offering—likely to result in share issuance and potential dilution
- The right of first refusal granted to Bowery Group LLC for future debt financings—indicating continued reliance on external capital
- Restrictions on dividends, repurchases, and related-party transactions—may limit certain shareholder actions
- Interest and default rates—implying significant financing costs if fully drawn
Corporate Governance and Risk Factors
The agreement defines multiple events of default, including bankruptcy, breach of representations, and material adverse changes. The company’s representations and warranties cover its financial statements, compliance, assets, intellectual property, and more. Investors should note that the company is not an emerging growth company, and its common stock is listed on NASDAQ under the symbol BRTX.
The credit facility is unsecured and does not create a trading market for the Loans, which are not registered under the Securities Act and are subject to transfer restrictions.
Conclusion
This financing development is a pivotal move for BioRestorative Therapies, Inc., providing immediate financial flexibility and paving the way for a potential capital raise through a public equity offering. Investors should closely follow subsequent announcements regarding the Qualified Public Equity Offering, as it could materially impact the company’s share value and future growth prospects.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to perform their own due diligence and consult with financial advisors before making any investment decisions. The information herein is based on publicly available filings and may be subject to change.
